Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Clinical trial NCT04892017 · TERMINATED

Trial details

NCT number: NCT04892017
Sponsor: Deciphera Pharmaceuticals, LLC
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer Advanced Solid Tumor Metastatic Solid Tumor

Start date: 2021-06-15
Primary completion: 2026-03-30
Enrollment: 91

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.